← All trials
NCT06886620
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 14, 2016
- Primary completion
- Feb 8, 2017
- Completion date
- Feb 8, 2017
- First posted
- Mar 20, 2025
- Last posted
- Mar 20, 2025
- Enrollment
- 14
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Genovate Biotechnology Co., Ltd.,Lead sponsor
- Cheng-Hsin General HospitalOfficial
- National Taiwan UniversityOfficial
- Chang Gung UniversityOfficial
- Taipei Veteran General hospitalOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.